The official blog of the Lung Institute.

Is COPD a Progressive Disease?

8 Aug 2017
| Under COPD, Lung Disease | Posted by | 4 Comments
Lung Graphic

Chronic obstructive pulmonary disease, or COPD, is a progressive condition that is characterized by respiratory difficulties. Oftentimes, COPD results from a persistent cycle of emphysema and chronic bronchitis — emphysema causes the alveoli (air sacs in the lungs) to lose elasticity, and chronic bronchitis causes the bronchioles (air passages) to become inflamed, leading to increased mucus production. COPD most frequently results from smoking cigarettes, but can also be caused by the inhalation of pollutants or by an alpha-1 antitrypsin deficiency.

As of this time, there is no cure for COPD, and because it is a progressive disease, its symptoms tend to worsen over time. Many physicians track the progression of COPD with the GOLD staging system, which uses the following four stages based on a patient’s FEV1 (forced expiratory volume in one second) score:

  • Stage 1 (very mild) — If a patient can forcefully exhale at least 80 percent of his or her normal lung capacity in one second, the GOLD system assigns a Stage 1 COPD progression. Patients who are ranked at this stage may notice coughing, slight airflow limitations or an increase in mucus production, but generally do not experience any other symptoms.
  • Stage 2 (moderate) — Patients who can forcefully exhale between 50 and 80 percent of their normal lung capacity in one second are ranked as having Stage 2 COPD progression. Many people begin experiencing recognizable COPD symptoms at this stage, including decreased airflow, breathlessness (particularly during physical activity), coughing, wheezing and phlegm/sputum production.
  • Stage 3 (severe) — Stage 3 COPD progression includes those patients who can forcefully exhale between 30 and 50 percent of their normal lung capacity in one second. Patients who are at this stage of COPD progression generally experience an increase in symptoms, particularly breathlessness and exhaustion, and may require intermittent hospitalization.
  • Stage 4 (very severe or “end stage”) — Stage 4 COPD progression includes those patients who can forcefully exhale less than 30 percent of their normal lung capacity in one second, as well as those who would otherwise be ranked at Stage 3 but also have low blood oxygen levels. Patients at this stage experience increased fatigue and breathlessness, and COPD flare-ups at this stage can sometimes be life-threatening.

Because individuals progress through these stages at different rates, it is not possible to accurately predict a COPD patient’s life expectancy. By tracking the progression of the condition using the above stages, however, physicians can continually adjust a patient’s COPD treatment plan to reflect that patient’s changing needs.

If you have been diagnosed with COPD, please call the Lung Institute today at (800) 729-3065 to speak with one of our caring team members. We offer innovative stem cell treatment options for COPD that can potentially promote healing from within the lungs (as opposed to simply treating symptoms) and may improve quality of life. Even if you believe you are in the early stages of COPD progression, we encourage you to seek treatment as soon as possible.


  1. Lung Institute

    6 months ago


    Thank you for your question. We are hopeful that insurance companies will offer insurance coverage in the near future. The cost of treatment varies based on specific condition and the treatment offered. For more information on financing and cost, please call (855) 313-1149 to speak one-on-one with a patient coordinator.



  2. Lung Institute

    6 months ago


    Thank you for your comment. People in all stages of COPD may be eligible for treatment. To speak to a representative about your mother’s specific condition and to learn more, please call (855) 313-1149 to speak with a patient coordinator, who will be happy to assist you.


    Lung Institute

  3. Angie Chavarria

    7 months ago

    So my mother has just encountered stage 4 COPD,. Does she stand a chance for stem cell candidate? Shes just getting weaker w the meds given to her but she still tries to hang in there. She is 79 but has will to live. Shes been bedridden fot a month and hasnt given up hope.

  4. Lesley Andring

    7 months ago

    I would love to get this stem cell treatment but it cost to much. Insurance doesn’t cover it. I understand why insurance doesn’t want to cover it because then the patients,would become healthier. Just doesn’t make sense. Insurance should cover this treatment. What are people’s options?

Your Comment

Your email address will not be published.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.